Click here to download the KEYNOTE-355 clinical data presentation
KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA in combination with chemotherapy is indicated for:
| Locally recurrent unresectable or metastatic triple‑negative breast cancer | ||||||
|---|---|---|---|---|---|---|
For use in
|
The first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥10 and who have not received prior chemotherapy for metastatic disease.1 | |||||
Dosing schedule
|
The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.1 | |||||
Duration of treatment
|
Treat until disease progression or unacceptable toxicity.1 | |||||
Clinical trial
|
KEYNOTE-355 was a phase 3 multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of KEYTRUDA in combination with paclitaxel, nab-paclitaxel, or gemcitabine and carboplatin in patients with locally recurrent unresectable or metastatic TNBC, regardless of tumour PD-L1 expression, who had not been previously treated with chemotherapy plus placebo in the metastatic setting.1 | |||||
|
||||||
| Locally recurrent unresectable or metastatic triple‑negative breast cancer | ||||||
|---|---|---|---|---|---|---|
|
For use in
|
The first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥10 and who have not received prior chemotherapy for metastatic disease.1 | |||||
|
Dosing schedule
|
The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.1 | |||||
|
Duration of treatment
|
Treat until disease progression or unacceptable toxicity.1 | |||||
|
Clinical trial
|
KEYNOTE-355 was a phase 3 multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of KEYTRUDA in combination with paclitaxel, nab-paclitaxel, or gemcitabine and carboplatin in patients with locally recurrent unresectable or metastatic TNBC, regardless of tumour PD-L1 expression, who had not been previously treated with chemotherapy in the metastatic setting.1 | |||||
|
Click here to download the KEYNOTE-355 clinical data presentation |
||||||
Refer to the Summary of Product Characteristics and Risk Minimisation materials available on the emc website before prescribing in order to help reduce the risk associated with KEYTRUDA.
Reference
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information and SmPC (Great Britain) & Prescribing Information and SmPC (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
GB-PDO-01875 | Date of Preparation: January 2022